Source: Pharmaceutical Technology
At the Black Health Forum 2024, HHS secretary Xavier Becerra detailed plans for improved access to sickle cell disease therapies. Credit: Kevin Dietsch via Getty Images. Rounding off US Black History Month, Xavier Becerra, secretary of the US Department of Health and Human Services (HHS), has said more work still needs to be done to allow health equity.
Free ReportHow is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
-->By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Thank you.You will receive an email shortly. Please check for download the Report.
Go deeper with GlobalData
Source: Pharmaceutical Technology
Source: Pharmaceutical Technology
The gold standard of business intelligence.
Related Company ProfilesVertex Pharmaceuticals IncCRISPR Therapeutics AGView all
“We are far from done in pushing the envelope when it comes to equity by design,” said Becerra.
At the HHS Black Health Forum 2024, held on 28 February, the secretary announced a project for gene therapies, beginning with work towards access to sickle cell disease treatments. “We now have, within our grasp, not just a treatment, but a cure for sickle cell disease,” added Becerra. However, he highlighted monetary barriers to treatment access. See Also:The health risks of ultra-processed foods (UPFs) are worse than we think
Source: Pharmaceutical Technology
Indena’s CDMO services: Health is a joint project Source: Pharmaceutical Technology
According to GlobalData’s pricing database, Casgevy has a US wholesale cost of $2.64 million whilst Lyfgenia wholesales at $3.72m in the US.
Becerra declared that the US Centers for Medicare and Medicaid Services (CMS) will soon begin an initiative to collaborate with as many states as possible to negotiate a deal with the pharmaceutical manufacturers of the two therapies. Headed by CMS administrator Chiquita Brooks La-Sure, the organisation plans to reach a deal on a reasonable price for gene therapies to increase access for patients. “If we do it together, we can bargain because we have the power of numbers behind us and we can negotiate the best deal,” says Becerra.
Sickle cell disease is the name of a group of diseases caused by dysfunction in the red blood cells. Symptoms of the disease include anaemia, increased risk of infection and, in some cases, stroke and death. The US Centers for Disease Control and Prevention (CDC) reports that the disease affects approximately 100,000 Americans, disproportionately occurring in one in every 365 Black or African-American births. Becerra called the audience to action saying: “Make sure that your states are joining in this voluntary effort …to drive down the price and get the best bargain for those who have sickle cell disease and who are on Medicaid.” At the forum, the HHS secretary raised other examples of the department’s health equity actions, highlighting the extension of Medicaid postpartum coverage. HHS currently has a programme, in partnership with Congress, that allows it to partner with states to deliver 365 days of postpartum care to new mothers. Becerra says 44 states have joined the programme since it launched, but he encouraged the remaining states to join the initiative.
Free ReportHow is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
-->By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Thank you.You will receive an email shortly. Please check for download the Report.